MedTrace Logo

A Study of [89Zr]-Oxine-NCR100 Injection for the Cellular Distribution

NCT07139431 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-08-24

No results posted yet for this study

Summary

This clinical study is to evaluate the biodistribution of \[89Zr\]-Oxine-NCR100 injection in subjects with knee osteoarthritis after local injection and the kinetic behavior characteristics of zirconium-labeled cells at the injection site and various organs or tissues. It is a single-dose, open-label study in adult KOA subjects.

Conditions

  • KOA

Interventions

BIOLOGICAL

NCR100

Subjects will receive a single injection of NCR100

Sponsors & Collaborators

  • Nuwacell Biotechnologies Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-29
Primary Completion
2026-03-06
Completion
2028-04-21

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07139431 on ClinicalTrials.gov